SS-31

SS-31, also known as Elamipretide, is a mitochondria-targeted tetrapeptide designed to address mitochondrial dysfunction by stabilizing the inner mitochondrial membrane. Its primary benefits include enhanced cellular energy (ATP) production, significant reductions in reactive oxygen species (ROS), and protection against apoptosis (programmed cell death). It is widely studied in the context of heart failure, muscle myopathies, and age-related cellular decline, where mitochondrial impairment is a primary driver of pathology. <br><br> The mechanism of action is unique; SS-31 selectively binds to cardiolipin, a phospholipid exclusively found in the inner mitochondrial membrane that is essential for the efficient function of the electron transport chain. By stabilizing cardiolipin, SS-31 prevents mitochondrial cristae from remodeling, reduces electron leakage, and minimizes the production of ROS. This action effectively restores mitochondrial bioenergetics, allowing cells with high energy demands—such as those in the heart, brain, and muscles—to function at optimal capacity. <br><br> Research backing for SS-31 is extensive, including numerous Phase II and Phase III clinical trials. It has been investigated for conditions ranging from primary mitochondrial myopathy to cardiovascular disease. The clinical data consistently show its potential to improve biomarkers of mitochondrial function and patient-reported outcomes in disorders characterized by energy failure, establishing SS-31 as a leader in mitochondrial-targeted therapeutics.